| Item type |
文献 / Documents(1) |
| 公開日 |
2018-03-08 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.2152/jmi.64.262 |
|
|
言語 |
ja |
|
|
関連名称 |
10.2152/jmi.64.262 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor |
|
言語 |
en |
| 著者 |
トミダ, チサト
ナガノ, ヒカル
ヤマギシ, ナオコ
内田, 貴之
オオノ, アヤコ
平坂, 勝也
二川, 健
(手嶋)近藤, 茂忠
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Recently, inhibition of tumor angiogenesis has become an important anti-cancer therapy. Tumor angiogenesis is regulated by multiple signaling pathways, including VEGF and VEGF receptor (VEGF-R), FGF and FGF receptor (FGF-R), and PDGF and PDGF receptor (PDGF-R) pathways. Thus, the antiangiogenic agents, such as regorafenib, simultaneously target those receptors on vascular endothelial cells. In addition to endothelial cells, cancer cells express the three receptors, suggesting that the antiangiogenic inhibitors affect tumor cells. In fact, we previously demonstrated that regorafenib directly acted on human colorectal cancer cells and accelerated their apoptosis resistance and migration capability. Thus, we here elucidated how regorafenib induced the malignant phenotypes in colorectal cancer cells. To identify the responsible receptor among the regorafenibtargeting proangiogenic receptors, we examined the effects of a potent selective inhibitor for VEGF-R, FGF-R or PDGF-R on apoptosis resistance and migration capability. We clarified that blockade of VEGF-R, but not FGF-R and PDGF-R, induced the malignant phenotypes. We confirmed that blocking of VEGF ligands derived from colorectal cancer cells also induced the phenotypes. These results suggest that regorafenib progressed the malignancy via prevention of autocrine and paracrine VEGF signaling in colorectal cancer cells. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
angiogenesis inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
regorafenib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
VEGF-R |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
tumor cell aggressiveness |
| 書誌情報 |
en : The Journal of Medical Investigation
巻 64,
号 3-4,
p. 262-265,
発行日 2017-08
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13496867 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13431420 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12022913 |
| 出版者 |
|
|
出版者 |
Faculty of Medicine Tokushima University |
|
言語 |
en |
| EID |
|
|
識別子 |
338761 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
jmi_64_3-4_262.pdf (224 KB)
